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ABSTRACT
Purpose: Pelvic bone metastases are difficult to treat because of complex pelvic 
bone anatomy and the proximity of normal organs. The adequacy of radiation dose 
and field coverage was evaluated.
Patients and methods: We analyzed 146 cases of pelvic bone metastases from 
HCC treated with radiotherapy (RT). Bone metastases were confirmed using CT/
MRI. Subjective pain response was assessed using the visual analogue scale, and 
treatment-related toxicity with the Common Terminology Criteria for Adverse Events 
v3.0. Local failure free survival (LFFS) and overall survival were estimated using the 
Kaplan-Meier method.
Results: The local control rate was 80.1% and the pain control rate was 68.5%. 
Compartmental target volume (CTV), encompassing the whole compartment of the 
involved bone, was found to be a significant factor (1-year LFFS, 78% vs. 50%; 
p=0.001). Sites of metastasis were categorized as either upper or lower pelvic bone; 
both categories showed improved local control with CTV. Metastatic lesions that 
received more than 50 Gy of EQD2 showed more partial response in pain after RT 
(58% vs. 79%; p=0.007). No patient showed toxicity higher than Grade IV.
Conclusion: Compartmental RT targeted to the involved bone was associated 
with improved local control and LFFS. High-dose radiation was associated with an 
improved treatment response.
INTRODUCTION
The bone is a major site of extrahepatic metastasis 
from hepatocellular carcinoma (HCC). Patients with 
terminal Barcelona-Clinic Liver Cancer stage D HCC 
require full symptomatic palliation for local disease 
or distant metastasis.[1] Palliative radiotherapy (RT) 
effectively manages symptoms in HCC patients with bone 
metastases, with pain response rates of approximately 
60-80%.[2–4] Pain, bone destruction causing mechanical 
instability, and pathological fractures are the most common 
manifestations of bone metastases. To date, several 
studies described clinical features and radiotherapeutic 
strategies in HCC patients with bone metastasis, and 
many studies have evaluated stereotactic body RT for 
spine metastasis.[5–8] Unlike vertebral metastases, few 
studies have evaluated HCC patients with pelvic bone 
metastasis. The pelvic skeleton supports the balance of 
the trunk and has a complex bone anatomy. Many organs 
such as the intestines, urinary bladder, and internal sex 
organs are located within or near the pelvis. With these 
considerations, RT planning for pelvic bone metastases is 
frequently challenging.
We analyzed the clinical outcomes including pain 
palliation and local control according to clinical features 
and radiotherapeutic parameters in HCC patients who 
received RT for pelvic bone metastases.
RESULTS
Patients
A total of 146 bone metastases from 89 patients were 
analyzed. Median patient age was 56 years (range, 36-79 
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years), and 70 patients (79%) were male. The most common 
viral background was hepatitis B virus (n=77; 86%), and 71 
patients (80%) were classified as Child-Pugh class A. Sixty-
five patients (72%) had a controlled primary tumor, while 24 
(28%) had an uncontrolled primary tumor. An uncontrolled 
primary tumor was defined as the presence of viable tumors 
in the liver or HCC progression (Supplementary Table 1). 
Bone metastasis (n=146) characteristics are summarized 
in Table 1. Thirty-two patients had multiple pelvic bone 
metastases. We categorized the sacrum and ilium as 
upper pelvic bone, and the acetabulum, pubic bone, and 
ischium as lower pelvic bone. Of 110 cases with other bone 
metastasis, the most common site was the T-spine (n=83), 
followed by the L-spine (n=75), scapulae (n=8), C-spine 
(n=7), ribs (n=6), sternum (n=5), and skull (n=4). There 
were 59 out of 146 cases (40%) receiving sorafenib, and 
there were 24 out of 59 cases (41%) were treated RT and 
sorafenib simultaneously.
Local control, pain control and survival analysis
The median follow-up time was 9.7 months (range, 
2.1-42.3 months). The local control rate (LCR) was 80.1%, 
the pain control rate was 68.5%, and the 1-year pain free 
interval (PFI) was 70%. The LCR and pain control rate 
according to bone metastasis characteristics are summarized 
in Table 2. There were more local failures and recurrences of 
pain in cases of pure osteolytic lesions than mixed metastasis 
(p=0.004 and 0.002, respectively). Cases of bone metastasis 
with soft tissue extension had more local failures (p= 0.025).
Local failure free survival (LFFS) regarding 
clinical target volume (CTV) is depicted in Figure 1. 
Compartmental target volume was a significant factor 
for LFFS (1-year LFFS, 78% vs. 50%; p=0.001). 
Bone metastasis characteristics according to CTV 
are summarized in Table 3. Lesions treated with 
compartmental target volume were less often classified 
as Child-Pugh class C (p=0.04) and were less osteolytic 
(not statistically significant). We performed subgroup 
analysis of bone metastasis characteristics. Sites were 
categorized into either upper or lower pelvic bone, and 
both categories showed improved local control with 
compartmental target volume treatment. Treatment with 
compartmental target volume showed improved local 
control over marginal target volume in cases without other 
bone involvement, soft tissue extension, and with mixed 
type bone metastasis (Table 4). A trend toward better local 
control was observed in cases of bone metastasis with 
primary controlled and single pelvic bone metastasis. 
Regarding pain control, however, no difference was 
detected between compartmental and marginal target 
volumes (Supplementary Table 2).
Table 1: Bone metastasis characteristics
Variable Group n %
Site Sacrum 44 30%
Ilium 43 29%
Acetabulum 26 18%
Pubic bone 17 12%
Ischium 16 11%
Site categorization Upper pelvic bone 87 67%
Lower pelvic bone 43 33%
Primary controlled Controlled 36 25%
Uncontrolled 110 75%
Number of pelvic bone metastasis Single 59 40%
Multiple 87 60%
Other bone involvement Present 110 75%
Absent 36 25%
Characteristics Mixed 136 93%
Pure osteolytic 10 7%
Soft tissue extension Present 41 28%
Absent 105 72%
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Table 2: Local control and pain control
Variable Group Local control 
(%)
p value Pain control 
(%)
p value
Site Sacrum (44) 89% 64%
Ilium (43) 70% 72%
Acetabulum (26) 88% 79%
Pubic bone (17) 77% 77%
Ischium (16) 82% 68%
Site categorization Upper pelvic bone (87) 75% 68%
Lower pelvic bone (43) 83% 70%
Primary controlled Controlled (36) 75% 0.254 58% 0.097
Uncontrolled (110) 82% 72%
No. of pelvic bone metastasis Single (59) 78% 0.588 71% 0.564
Multiple (87) 82% 67%
Other bone involvement Present (110) 81% 0.683 67% 0.579
Absent (36) 78% 72%
Characteristics Mixed (136) 83% 0.004 72% 0.002
Pure osteolytic (10) 40% 20%
Soft tissue extension Present (41) 68% 0.025 76% 0.247
Absent (105) 85% 66%
Figure 1: Local failure free survival according to target volume.
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According to pelvic metastasis subsites, treatment 
with compartmental target volume showed better local 
control with the exception of iliac bone metastasis. 
Local control was very poor with both compartmental 
and marginal target volume in cases of iliac bone 
metastasis, and no difference in local control was detected 
between target volumes. Therefore, in cases of iliac 
bone metastasis, higher dose RT should be considered. 
For patients with other bone involvement, no difference 
was detected according to treatment volume. Therefore, 
treatment volume according to bone marrow volume 
should be considered.
Because different fractional doses were used, we 
calculated RT dose as equivalent 2 Gy fractions (EQD2) 
Table 3: Bone metastasis characteristics according to target volume
Variable
Compartmental
(n=85)
n (%)
Marginal
(n=61)
n (%)
p value
Child-Pugh class A 64 (75%) 46 (75%) 0.04
B 17 (20%) 6 (10%)
C 4 (5%) 9 (15%)
Primary controlled 23 (27%) 13 (21%) 0.276
Single pelvic bone metastasis 36 (42%) 23 (38%) 0.572
Other bone involvement 66 (78%) 44 (72%) 0.446
Soft tissue extension 25 (29%) 16 (26%) 0.673
Metastasis 
characteristic Osteolytic 3 (4%) 7 (12%) 0.06
Table 4: Local control according to target volume
Variable Group
Local control rate (%)
p value
Compartmental Marginal
Pelvic subsite Sacrum (44) 63% 19% 0.38
Ilium (43) 30% 30% 0.31
Acetabulum (26) 95% 75% 0.125
Pubic bone (17) 86% 57% 0.16
Ischium (16) 89% 50% 0.135
Site categorization Upper pelvic bone (87) 86% 68% 0.044
Lower pelvic bone (43) 59% 13% 0.001
Primary controlled Controlled (36) 61% 39% 0.051
Uncontrolled (110) 59% 41% 0.371
Number of pelvic bone metastasis Single (59) 62% 38% 0.06
Multiple (87) 58% 42% 0.245
Other bone involvement Present (110) 53% 47% 0.234
Absent (36) 75% 25% 0.023
Soft tissue extension Present (41) 60% 40% 0.428
Absent (105) 61% 39% 0.022
Metastasis characteristic Mixed (136) 89% 74% 0.023
Pure osteolytic (10) 67% 29% 0.5
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assuming an α/β ratio of 10 Gy. There were 14 out of 
146 cases (10%) received more than 50 Gy of EQD2; 
sacrum (n=4), ilium (n=6), and lower pelvic bone (n=4). 
Metastatic lesions that received more than 50 Gy of EQD2 
showed more partial response in pain after RT (58% vs. 
79%; p=0.006).
Effects of targeted agent (sorafenib) were analyzed. 
Adding systemic treatment had no effect on local control, 
pain control and survival.
Median OS was 3.8 months, and no difference in OS 
was detected between different CTVs (Figure 2).
Toxicity
Acute RT-related toxicities are summarized in Table 
5. Grade IV neutropenia and thrombocytopenia (n=4 and 
n=3, respectively) were observed with compartmental target 
volume treatment. No grade IV toxicities were observed 
with marginal target volume treatment. However, these 
were not statistically significant (p=0.087 for neutropenia 
and p=0.162 for thrombocytopenia, respectively).
DISCUSSION
The incidence and distribution of extrahepatic 
bone metastasis
Extrahepatic metastases from primary HCC confer 
poor prognoses. Frequent sites of HCC metastasis 
include the lungs (55%), lymph nodes (53%), and bone 
(28%).[9] The bone is the third most common site of 
extrahepatic metastasis, and Xiang et al. reported that 
the frequency of bone metastases in 350 HCC patients 
who had undergone curative resection was 11.7%.[10] 
Fukutomi et al. reported that the incidence of bone 
metastases from HCC is increasing. Bone metastasis 
was found in 12 of 269 patients with HCC (4.5%) 
between 1978 and 1987, and 52 of 404 patients with 
HCC (12.9%) between 1988 and 1997. More recently, 
the incidence of bone metastasis has significantly 
increased (p<0.0004). [11] The vertebrae are the 
most common sites of HCC bone metastasis (68.8%). 
Thoracic vertebrae are most frequently involved, 
followed by lumbar and cervical vertebrae. In a study of 
203 patients with HCC, He et al. reported that the axial 
skeleton was the most common site of bone metastasis, 
with metastases occurring most frequently in the spine 
(46.0%), pelvis (18.5%), and ribs (15.9%). [5] In the 
present study, we focused on HCC patients with pelvic 
bone metastases because only a few case studies have 
evaluated radiotherapy for pelvic metastases, [12] and 
because there exists no consensus about target volume 
and radiation dose for HCC pelvic bone metastases. 
When the pelvic bone is categorized into the three parts, 
the sacroiliac joint lumbar spine (5.9%) is the most 
frequent site of pelvic bone metastasis, followed by the 
ilium (4.0%) and the sacrum (3.5%). [5]
Figure 2: Overall survival according to target volume
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Clinical results from EBRT dose-response 
relation and toxicity
He et al. reported that partial pain relief was achieved 
in 70.2% of patients (144 of 205 patients), complete pain 
relief was achieved in 29.3% (60 patients), and overall pain 
improved in as much as 99.5% of HCC patients.[5] There 
was no dose-response relationship for palliation of bone 
metastasis, but the retreatment rate was higher in patients 
with expansile soft tissue. In this study, 40% of HCC 
bone metastases showed hypervascular soft-tissue mass.
[5] Concerning pelvic bone marrow, several studies have 
evaluated the dose-volume effects of pelvic bone marrow 
radiotherapy in rectal and cervical cancer patients. Mell 
et al. contoured pelvic bone marrow (BM) and evaluated 
dosimetric parameters associated with acute hematologic 
toxicity in cervical cancer patients undergoing concurrent 
chemotherapy and intensity-modulated pelvic radiotherapy.
[13] Low pelvic bone marrow dose was associated with 
increased Grade II or worse leukopenia and neutropenia 
(p=0.006 and p=0.037, respectively). Mell et al. suggested 
that even low dose irradiation to the pelvic bone frequently 
induces hematologic toxicity and that the volume of 
irradiated pelvic bone marrow is important. Lee et al. also 
described the volume of red bone marrow as an independent 
risk factor associated with hematologic toxicity (p=0.014).
[14] The present study evaluates pelvic bone radiotherapy 
for pelvic bone metastasis. Determining the target volume 
is very important in these patients because pelvic bone 
marrow volume is critical for hematologic toxicity.[14] 
P53 has been suggested to play a key role in determining 
how a cell responds to RT. Gomes et al. reported that 
irradiation induced a decrease in cell survival when P53 was 
overexpressed in vitro.[15] We were unable to analyze P53 
expression owing to the retrospective nature of this study.
Grade IV neutropenia and thrombocytopenia (n = 
4 and n = 3, respectively) were more frequently observed 
with compartmental target volume treatment than with 
marginal target volume. Therefore, we suggest that 
treatment volume should be decided according to bone 
marrow volume and other bone involvement. One case of 
isolated metastatic HCC arising from the pelvic bone has 
been described: a 73-year-old man presented with a large 
mass on the pelvic bone (13 × 10 cm). He was treated with 
radiotherapy and transarterial chemoembolization to the 
pelvic bone followed by chemotherapy, resulting in near 
complete tumor regression.[12]
Combination of sorafenib and radiation therapy
There is little information about the combined 
radiotherapy and sorafenib for bone metastases in patients 
with hepatocellular carcinoma. In our previous report, the 
feasibility of sorafenib combined with radiation therapy in 
18 patients with hepatocellular carcinoma was evaluated.
[16] The in-field response rate was 100% in the primary 
group and 60% in the measurable metastasis group. 
Toxicities of grade 3-4 related combined treatment were 
duodenal bleeding in 1 (6%) patient and elevation of 
aspartate transaminase in 1 (6%) patient. In recent phase 
II study, the tolerance and toxicities of conventionally 
fractionated radiation therapy (2-2.5 Gy per fraction; 
dose range 40-60 Gy) with sorafenib were evaluated.[17] 
Hepatic toxicities were major determinant of the combined 
treatment in this study as follows, six patients (15%) 
developed treatment-related hepatic toxicity grade ≥ 3, 
and 3 of them were fatal. Brade et al. reported the phase 
I study of the combination of sorafenib with stereotactic 
body radiation therapy for hepatocellular carcinoma.[18] 
In this study, clinical dose-limiting toxicities (grade 3 large 
bowel bleeding and grade 4 bowel obstruction) were noted 
dependent on the irradiated volume and dose of sorafenib. 
Therefore, the combination should be used with caution 
and recommended with a clinical trial.
Clinical target volume of pelvic bone metastasis 
from HCC
Metastatic lesions are typically osteolytic, although 
sclerotic lesions can be encountered from primary 
tumors such as prostate or breast carcinoma.[19] He et 
al. reported that purely osteolytic lesions were present in 
2.4% of 205 HCC patients with bone metastasis.[5] Most 
lesions (97.6%) had a combination of both osteolytic and 
osteoblastic components. For pelvic bone HCC metastases 
in the present study, only 7.1% were pure osteolytic 
lesions, and 28.1% had soft tissue extension. Although the 
number of pure osteolytic lesions was small (n = 10), local 
control and pain control were quite poor (29% and 14%, 
respectively) when such lesions were treated with marginal 
target volume. Therefore, we propose that compartmental 
treatment should be considered in these patients.
For target volume delineation, some guidelines 
and clinical recommendations exist for spine metastases 
in metastatic breast cancer patients. For example, CTV 
Table 5: Toxicity by target volume
Toxicity (Grade)
Compartmental (n=78) Marginal (n=68)
I II III IV I II III IV
Anemia 9 15 1 0 8 10 4 0
Neutropenia 5 17 7 4 7 12 10 0
Thrombocytopenia 9 10 7 3 7 11 8 0
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should include the complete vertebral body in cases 
of vertebral involvement.[20] Although the pelvis is a 
typical metastatic site, little consensus exists regarding 
target volume delineation for radiotherapy of pelvic 
bone metastases. Because the pelvis has a curved 
shape and encompasses bowel loops and the bladder, 
contouring the target volume and protecting the organs 
at risk is challenging. In the present study, target volume 
encompassing the gross tumor plus a wide margin 
encompassing pelvic bone marrow showed significantly 
improved local control as compared to clinical target 
volume plus the margin of the involved metastatic bone 
tumor (p=0.001), without significantly increasing toxicity.
Recent technological advances, such as intensity 
modulated radiotherapy and stereotactic body 
radiotherapy, have enabled more successful radiation 
treatment by delivering a substantial dose of radiation 
to the tumor and sparing healthy normal tissues.[21] 
Although many studies have evaluated clinical features 
and radiotherapeutic strategies in patients with spinal bone 
metastasis, few studies have been performed for HCC 
patients with pelvic bone metastasis. Although the present 
study is a retrospective analysis, the results of this study 
provide practical guidelines for radiation treatment for 
HCC patients with pelvic bone metastasis. Future clinical 
trials will focus on comparing treatment results using 
different target volumes, or different treatment strategies.
In conclusion, radiotherapy for pelvic bone 
metastases provides considerable pain palliation and local 
control for HCC patients. Treatment of the entirety of the 
involved bone was associated with improved local control 
rates and local failure-free survival. High-dose radiation 
was associated with an improved treatment response.
PATIENTS AND METHODS
Patient selection
The medical records of HCC patients who 
underwent RT for bone metastasis between 2005 and 2011 
were retrospectively reviewed. Eligibility criteria for this 
study were: (1) age ≥ 18 years; (2) an initial diagnosis 
of primary HCC; (3) a diagnosis of bone metastasis; (4) 
the presence of pelvic bone metastasis, which includes the 
sacrum, iliac bone, pubic bone, ischium, and acetabulum; 
and (5) radiation dose > 20 Gy in a EQD2 assuming 
an α/β ratio of 10 Gy. A diagnosis of bone metastasis 
was based on the presence of symptoms and radiologic 
imaging studies. Radiologic imaging studies included 
computed tomography (CT), magnetic resonance imaging 
(MRI), and whole body bone scan (WBBS). CT or MRI 
was considered confirmatory to determine the presence 
of soft-tissue extension with bone destruction and the 
extent of osteolytic or osteoblastic metastasis. Histologic 
confirmation of bone metastasis was not mandatory in this 
study. We analyzed 146 cases from 89 patients with pelvic 
bone metastasis from HCC treated with RT.
Metastasis characteristics were categorized as either 
pure osteolytic or mixed (osteolytic and osteoblastic). Pure 
osteolytic metastasis was defined as the presence of bone 
destruction with no new bone formation, as detected by 
CT or MRI, as well as no increased hot uptake during 
the WBBS. Mixed metastasis was defined as new bone 
formation in the involved bone that was visible by CT or 
MRI as well as increased hot uptake during the WBBS.
Treatment
Planning CT was performed on patients in a supine 
position. We defined gross tumor volume (GTV) as the 
volume of the metastatic tumor detected on CT or MRI. 
We defined CTV as follows: compartment target volume, 
which encompassed the gross tumor plus a wide margin 
considering pelvic compartments; or marginal target volume, 
which encompassed the gross tumor plus adequate margin. 
Detailed explanations of compartment target volumes are 
as follows: (1) when a metastatic lesion was present in 
the sacrum, compartment target volume encompassed the 
whole sacrum; (2) when a metastatic lesion was present in 
the iliac bone, compartment target volume encompassed 
the entire iliac bone including the iliac wing; (3) when a 
metastatic lesion was present in the pubic bone, ischium 
or acetabulum, compartment target volume encompassed 
the entirety of the pubic bone, ischium, and acetabulum. 
GTV, compartment target volume, and marginal target 
volume are shown in Figure 3 and Supplementary Figure 
1. Figure 3a shows a patient treated with compartmental 
target volume. A 72-year-old man had metastasis to the 
left iliac bone with soft tissue extension. He was treated 
with three-dimensional conformal radiotherapy (3D-CRT) 
at a dose of 40 Gy in 16 fractions. Pain was decreased 
according to the visual analogue scale (VAS) from 6 to 2, 
and the metastatic lesion was controlled until his 10-month 
follow-up examination. Figure 3b show a patient treated 
with marginal target volume. A 68-year-old man had a right 
acetabulum metastasis. He received 45 Gy in 15 fractions 
using 3D-CRT. His pain was decreased from VAS 8 to 
3, but a right pubic bone metastasis at the margin of the 
initial RT field was discovered at his 18-month follow-up 
examination. After local failure, he received re-irradiation 
with compartmental target volume encompassing entire 
lower pelvic bone. Supplementary Figure 1 shows GTV, 
compartmental CTV, and marginal CTV. Supplementary 
Figures 1a, b, and c show target volumes for sacrum, iliac, 
and lower pelvic bone, respectively. We selected a patient 
without bone metastasis and delineated target volumes to 
show the difference between different CTVs. Seventy-eight 
(53%) of 146 cases were treated with compartment target 
volume, and the remaining 68 (47%) cases were treated 
with marginal target volume. CTV was modified to reduce 
the dose to organs at risk (OARs), such as the small bowel, 
bladder, rectum, and anus. For planning target volume 
(PTV), a 0.7 cm margin was applied to CTV considering 
patient movement and daily setup error.
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Sixteen patients (11%) were treated with two-
dimensional RT, 119 (82%) with 3D-CRT using 6 MV 
photons generated from a linear accelerator, and 11 (7%) 
with intensity-modulated radiotherapy (IMRT) using 
tomotherapy. The median RT dose was 35 Gy (range, 
17.5-60 Gy), and the median fractional dose was 3 Gy 
(range, 2.5-6 Gy). The most commonly used RT schedule 
was 30 Gy in 10 fractions.
Evaluation
The Child-Pugh classification is calculated from 
5 subscores: 3 objective clinical laboratory values (total 
bilirubin, serum albumin, and international normalized 
ratio) and 2 subjective variables (the severity of ascites 
and hepatic encephalopathy). Each variable is scored 
1-3, with 3 indicating the most severe derangement. A 
total score of 5-6 points is classified as A, 7-9 points is 
classified as B, and 10-15 points is classified as C.
The pain response was assessed as a subjective 
pain response using the VAS. VAS is used to describe 
the intensity of pain or how much pain the patient reports 
feeling., The patient is asked to identify how much pain he 
or she is feeling on a numeric rating scale from 0 (no pain) 
to 10 (the worst pain that he or she can imagine). Patients 
were asked to report the level of pain before, immediately 
after, and 1 month after treatment. A positive response was 
defined as a ≥ 50% reduction in the VAS numerical pain 
rating. Responses were evaluated for a total of 1 month, 
beginning with the first day of treatment.
Treatment-related toxicities were assessed at every 
follow-up examination. Toxicity was monitored according 
to the Common Terminology Criteria for Adverse Events 
v3.0 (CTCAE v3.0), through a physical examination and 
laboratory testing for levels of hemoglobin, white blood 
cells, and platelets, both during RT treatment and after 
completion of the RT schedule.
Statistical analysis
The primary endpoint of this study was LCR. Local 
failure was defined as recurrence of the tumor within the RT 
filed of a treated bone at any point after RT. Overall survival 
(OS) was calculated from the date of RT inception to the 
date of death or the last follow-up. The PFI was calculated 
from the date of RT inception to the date of pain recurrence 
Figure 3: Compartmental target volume and marginal target volume. a. Compartmental target volume for iliac bone metastasis. 
A 72-year-old man had a left iliac bone metastasis with soft tissue extension. He was treated with compartmental target volume and a dose 
of 40 Gy in 16 fractions. b. Marginal target volume for acetabulum bone metastasis. A 68-year-old man had a right acetabulum metastasis. 
He received 45 Gy in 15 fractions with marginal target volume. Gross tumor volume (red line), Clinical target volume (green line).
a
b
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or the last follow-up. OS, LFFS, and PFI were calculated via 
the Kaplan–Meier method using a log-rank test to estimate 
statistically significant differences. Factors affecting OS, 
LFFS, and PFI were identified using a Pearson’s χ2 test or a 
Fisher's exact test. Continuous variables were analyzed using 
a Mann-Whitney U test and a Student’s t-test. We considered 
p values <0.05 significant. For all analyses, SPSS version 
20.0.0 (IBM Corporation; Armonk, NY, USA) was used.
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